Martino E, Placidi G F, Sardano G, Mariotti S, Fornaro P, Pinchera A, Baschieri L
Ann Endocrinol (Paris). 1982 Jul-Sep;43(4):269-76.
The effects of lithium carbonate on thyroid was evaluated in 40 consecutive psychiatric patients on long-term treatment with this drug. Five patients had clinical and/or biochemical hypothyroidism. Twenty four (60%) subjects showed goiter of different size, including very large glands. A very high prevalence of goiter (87%) was observed in the 15 patients coming from a moderate endemic area. A lower incidence of goiter (44%) was found in subjects coming from non endemic areas. Goiter was associated with significantly elevated serum thyroglobulin concentration similar to that reported in endemic or sporadic nontoxic goiter. None of 25 psychiatric patients not receiving lithium therapy was hypothyroid and only three (12.5%) of them showed a small size goiter. These data indicate a very high prevalence of thyroid enlargement in patients on lithium therapy and suggest the opportunity to institute a prophylactic thyroid hormone treatment at least in subjects coming from endemic areas.
对40例连续使用碳酸锂进行长期治疗的精神科患者,评估了碳酸锂对甲状腺的影响。5例患者有临床和/或生化性甲状腺功能减退。24例(60%)受试者出现不同大小的甲状腺肿,包括非常大的腺体。在来自中度地方性甲状腺肿流行区的15例患者中,观察到甲状腺肿的患病率非常高(87%)。在来自非流行区的受试者中,甲状腺肿的发生率较低(44%)。甲状腺肿与血清甲状腺球蛋白浓度显著升高有关,类似于地方性或散发性非毒性甲状腺肿中报道的情况。25例未接受锂治疗的精神科患者均无甲状腺功能减退,其中只有3例(12.5%)有小的甲状腺肿。这些数据表明,接受锂治疗的患者甲状腺肿大的患病率非常高,并提示至少对来自流行区的患者应进行预防性甲状腺激素治疗。